Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisaka, Yasuhito, Kurata, Takayasu, Tanaka, Kaoru, Kudo, Toshihiro, Okamoto, Kunio, Tsurutani, Junji, Kaneda, Hiroyasu, Okamoto, Isamu, Namiki, Masayuki, Kitamura, Chifumi, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387254/
https://www.ncbi.nlm.nih.gov/pubmed/25502863
http://dx.doi.org/10.1007/s10637-014-0196-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387254/
https://www.ncbi.nlm.nih.gov/pubmed/25502863
http://dx.doi.org/10.1007/s10637-014-0196-0

Ejemplares similares